OMEICOS Therapeutics GmbH
OMEICOS Therapeutics GmbH is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at OMEICOS Therapeutics GmbH.
OMEICOS Therapeutics GmbH is a company.
Key people at OMEICOS Therapeutics GmbH.
Key people at OMEICOS Therapeutics GmbH.
OMEICOS Therapeutics GmbH is a Berlin-based clinical-stage biopharmaceutical company developing first-in-class small molecule therapeutics that target natural cell-protective pathways derived from omega-3 fatty acid metabolism.[1][2][4] Its lead asset, OMT-28, is an orally available compound activating the AMPK/SIRT-1/PGC1-alpha axis to reduce mitochondrial dysfunction, oxidative stress, inflammation (e.g., lowering GDF-15 and IL-6 biomarkers), and fibrosis, addressing high-unmet-need diseases like primary mitochondrial disease (PMD), cardiovascular conditions (atrial fibrillation, coronary artery disease), and ophthalmology (e.g., wet AMD).[1][2][5] OMEICOS serves patients with cardio/renal, metabolic/inflammatory, vascular/eye, and mitochondrial disorders, solving problems of chronic inflammation and organ protection where current therapies fall short, such as avoiding invasive eye injections.[2][3][5] The company shows strong growth momentum, with OMT-28 completing Phase 2 enrollment in PMD (PMD-OPTION study, top-line data mid-2025), positive Phase 2 atrial fibrillation results (PROMISE-AF), and plans for coronary artery disease proof-of-concept, backed by VC financing and grants.[2][3][4]
OMEICOS was spun out in June 2013 from the Max Delbrück Center for Molecular Medicine (MDC) in Berlin to explore stabilized epoxyeicosanoids—bioactive lipid mediators from omega-3 pathways—for therapeutic use, holding exclusive worldwide IP licenses from MDC and UT Southwestern.[3][4] Co-founder and CEO/CSO Robert Fischer, a PhD in cardiovascular physiology and board-certified internist with clinical cardiology experience at Charité – Universitätsmedizin Berlin, drives the vision of translating preclinical research into treatments for unmet needs.[4] Key milestones include selecting OMT-28 as lead in 2014 after preclinical validation, first-in-human Phase 1 data in 2018 (safe in 75 volunteers, later 162 total), Phase 2 atrial fibrillation initiation, US subsidiary in 2017, Series B financing in 2022, and PMD Phase 2 approval in 2023—achieving clinical proof-of-concept in under six years via a lean organization.[2][4]
OMEICOS rides the wave of mitochondrial medicine and bioactive lipid therapeutics, targeting root causes like oxidative stress and chronic inflammation in aging-related diseases amid rising cardio-metabolic and rare disease burdens.[2][5] Timing aligns with validated biomarker-outcome links (e.g., IL-6/GDF-15 reduction predicting CV event drops) and shifts toward oral alternatives to injectables, fueled by omega-3 research advances post-major trials like REDUCE-IT.[2] Market tailwinds include orphan drug incentives for PMD, booming ophthalmology (wet AMD market >$10B), and inflammation-focused CV investments, positioning OMEICOS to influence biotech by validating epoxyeicosanoids as a new class—potentially expanding to neoplasms and beyond via pipeline analogs.[3][5][6]
OMEICOS is poised for inflection with PMD-OPTION top-line data mid-2025, likely fueling partnerships or Phase 2b in coronary artery disease and ophthalmology proof-of-concepts.[2][3] Trends like AI-driven biomarker validation and mitochondrial therapeutics will accelerate its path, evolving its influence from niche PMD innovator to broad cardio-inflammatory leader—unlocking natural pathways to redefine organ protection, much like its origin in omega-3 breakthroughs continues to deliver clinical wins.[2][4][5]
